NCT07749664Not yet recruiting
DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients
Developmental Endothelial Locus-1 Serum Level and Its Relation With Thromboxane A2 and Platelet Count in Patients With Diabetic Nephropathy
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression. Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction. This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity. This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 29 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Aswan University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07749664
What you commit to
- Study type: Observational
- Planned participants: 80
- From 1 Sept 2026 to the primary completion date, 1 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have undergone recent surgery.
Other illness
- \- Patients with known hepatic disease.
- Patients with significant cardiovascular disease.
- Patients with malignancy.
- Patients with known hematological disorders or hypercoagulable states.
Lab values
- Patients receiving medications that significantly affect platelet function.
Who the study is looking for
- Adult patients aged between 18 and 70 years.
- Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings.
- Patients undergoing evaluation or follow-up for diabetic kidney disease.
- Ability and willingness to provide informed consent.
Age in the registry: 18 years to 70 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.